American Society of Hirudotherapy

Leech Metalloprotease Inhibitor

TIMP / netrin-domain metalloprotease inhibitor variant in leech salivary transcriptome — putative MMP regulator at bite site.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Leech Metalloprotease Inhibitor compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLeech Metalloprotease Inhibit…22 kDa
Molecular weight (kilodaltons) of Leech Metalloprotease Inhibitor (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
TIMP / netrin-domain metalloprotease inhibitor variant in leech salivary transcriptome — putative MMP regulator at bite site.
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

Predicted metalloprotease-inhibitor activity does NOT establish clinical efficacy. No FDA-approved derivative exists.

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
22,000 Da
Source species
Hirudo medicinalis
Discovered
2018
Leech Metalloprotease Inhibitor molecular structure

Biological Targets

  • matrix metalloproteinases (MMP-2 / MMP-9 predicted)

External Resources

    Related Proteinase Inhibitor Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.